<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Gliclazide MR and Metformin &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/gliclazide-mr-and-metformin/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 21 Oct 2025 13:31:23 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Gliclazide MR and Metformin &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Gliclazide Boosts Metformin for Uncontrolled Diabetes Costs</title>
		<link>https://bioengineer.org/gliclazide-boosts-metformin-for-uncontrolled-diabetes-costs/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 21 Oct 2025 13:31:17 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Gliclazide MR and Metformin]]></category>
		<category><![CDATA[Healthcare cost analysis]]></category>
		<category><![CDATA[Type 2 diabetes cost-effectiveness]]></category>
		<category><![CDATA[UAE diabetes management]]></category>
		<category><![CDATA[Uncontrolled diabetes treatment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/gliclazide-boosts-metformin-for-uncontrolled-diabetes-costs/</guid>

					<description><![CDATA[The management of Type 2 diabetes has become a subject of intense scrutiny as the prevalence of this chronic disease continues to rise globally. Among the diverse therapeutic approaches available, the combination of medications has garnered significant attention in clinical practice, particularly in regions with a high burden of diabetes. A recent study led by [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">284389</post-id>	</item>
	</channel>
</rss>
